



King Pharmaceuticals, Inc.  
Research and Development  
CentreGreen Two, Suite 300  
4000 CentreGreen Way  
Cary, NC 27513

Eric G. Carter, PhD, MD  
Chief Science Officer

April 30, 2008

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals<sup>®</sup>, Inc. has decided to discontinue the manufacture of Tilade<sup>®</sup> Inhaler (nedocromil sodium inhalation aerosol).

This decision is based upon many factors, including our inability to identify a qualified manufacturer for a chlorofluorocarbon propellant inhaler. TILADE<sup>®</sup> will remain available through pharmacies and wholesalers until current supplies are depleted.

TILADE<sup>®</sup> is distributed through King Pharmaceuticals<sup>®</sup>, Inc. No additional product will be available after King, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

TILADE<sup>®</sup> Inhaler is indicated for maintenance therapy in the management of adult and pediatric patients 6 years and older with mild to moderate asthma.

Important Safety Information:

TILADE<sup>®</sup> Inhaler is contraindicated in patients who have shown hypersensitivity to nedocromil sodium or other ingredients in this preparation. TILADE<sup>®</sup> Inhaler (nedocromil sodium inhalation aerosol) is not a bronchodilator and, therefore, should not be used for the reversal of acute bronchospasm, particularly status asthmaticus. The role of TILADE<sup>®</sup> as a corticosteroid-sparing agent in patients receiving oral or inhaled corticosteroids remains to be defined. If systemic or inhaled corticosteroid therapy is reduced in patients receiving TILADE<sup>®</sup>, careful monitoring is necessary. Common adverse reactions include unpleasant taste, coughing, pharyngitis, rhinitis, upper respiratory infection, bronchospasm, and headache.

Sincerely,

A handwritten signature in dark ink, appearing to read "Eric Carter", is written over a light blue horizontal line.

Eric Carter, PhD, MD  
Chief Science Officer

**Please see accompanying full Prescribing Information.**

TILADE is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals<sup>®</sup>, Inc.

Copyright © 2008 King Pharmaceuticals<sup>®</sup>, Inc. All rights reserved. MSB0001 Printed in U.S.A. 5/2008